Navigation Links
PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings
Date:12/4/2009

OKLAHOMA CITY, Dec. 4 /PRNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc. (Pink Sheets: PDRX) today announced revenue of $5,012,334 for the first quarter ended September 30, 2009, a 24% decrease over the same period last year. Operating income and net income for the quarter were $133,681 and $80,402, respectively, each a 70% decrease over the same period last year.

Results were impacted by a decrease in pharmacy sector sales. This trend is expected to continue throughout the rest of the fiscal year. In this economic environment, the company is focused on three main actions; working with customers to provide high value products at the lowest cost, increasing focus on expense management and targeting investment into the highest priority strategic opportunities.

ABOUT THE COMPANY:

PD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers and healthcare providers as a progressive and responsive practice.

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic conditions and factors affecting the industry.


Jack L. McCall, EVP & COO
Ph. 405-942-3040 / jlm@pdrx.com

SOURCE PD-Rx Pharmaceuticals, Inc.


'/>"/>
SOURCE PD-Rx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PD-Rx Completes Call for Preferred A Stock
2. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
3. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
7. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
8. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
9. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
10. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
11. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, ... recognized for adherence to the highest standards of trauma, maternity, cancer and chronic ... center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the American ...
(Date:12/8/2016)... ... ... Vida Health, the digital health platform that pairs individuals with ... . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect Ventures. Vida ... are managing chronic conditions or simply want to improve their health. Canvas ...
(Date:12/8/2016)... ... ... Coppin Insurance Agency, an insurance and financial planning firm based in Lee ... is embarking on a charity drive with the goal of providing support and donations ... Bank of Southwest Florida works to provide fresh and nutritious food free of charge ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: